tiprankstipranks
Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
PremiumCompany AnnouncementsRevance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
2M ago
Revance sees FY24 product revenue at least $280M
PremiumThe Fly
Revance sees FY24 product revenue at least $280M
2M ago
Revance reports Q4 EPS (62c), consensus (72c)
PremiumThe Fly
Revance reports Q4 EPS (62c), consensus (72c)
2M ago
Revance announces CMS assigns permanent J-code for Daxxify
PremiumThe FlyRevance announces CMS assigns permanent J-code for Daxxify
3M ago
Revance price target lowered to $10 from $35 at Barclays
PremiumThe Fly
Revance price target lowered to $10 from $35 at Barclays
3M ago
Revance downgraded to Neutral from Buy at Mizuho
PremiumThe Fly
Revance downgraded to Neutral from Buy at Mizuho
3M ago
Revance price target lowered to $30 from $33 at Goldman Sachs
PremiumThe FlyRevance price target lowered to $30 from $33 at Goldman Sachs
5M ago
Revance price target lowered to $40 from $65 at TD Cowen
PremiumThe Fly
Revance price target lowered to $40 from $65 at TD Cowen
5M ago
Revance expects to reach positive adjusted EBITDA in 2025
PremiumThe Fly
Revance expects to reach positive adjusted EBITDA in 2025
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100